Source:http://linkedlifedata.com/resource/pubmed/id/15257683
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
7
|
pubmed:dateCreated |
2004-7-19
|
pubmed:abstractText |
Beta2-microglobulin (beta2-MG) is a pharmacodynamic marker of interferon-beta activity in multiple sclerosis (MS). Its role in the natural course of the disease is not fully known. We analyzed the spontaneous fluctuation of beta2-MG in free-treatment MS patients during a short-time course to quantify beta2-MG as a marker of disease activity/progression. Thirty MS patients were clinically assessed and imaged monthly over a 3-month period. Sera were collected concomitantly for the evaluation of beta2-MG, by means of an enzyme-linked immunosorbent assay. Sera from 20 healthy individuals (HI) were drawn and used as controls. The Mann-Whitney test was used when appropriate and time effect on radiological and biological measures was assessed by means of the random effect models. Eight (26.7%) patients experienced a clinical relapse but three (10%) required steroid treatment. A reduction in the contrast-enhancing lesion load (P = 0.02) and a trend (P = 0.07) toward a decrease in brain parenchyma fraction were observed. Baseline levels of beta2-MG were similar in patients and HI. Patients' beta2-MG values increased over the 3-month time period (P = 0.05) but did not exceed those detected in HI at any time point. These results failed to demonstrate the validity of beta2-MG as a surrogate marker of disease in MS.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
1351-5101
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
11
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
455-60
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:15257683-Adult,
pubmed-meshheading:15257683-Biological Markers,
pubmed-meshheading:15257683-Cohort Studies,
pubmed-meshheading:15257683-Female,
pubmed-meshheading:15257683-Humans,
pubmed-meshheading:15257683-Male,
pubmed-meshheading:15257683-Multiple Sclerosis, Relapsing-Remitting,
pubmed-meshheading:15257683-Predictive Value of Tests,
pubmed-meshheading:15257683-beta 2-Microglobulin
|
pubmed:year |
2004
|
pubmed:articleTitle |
beta2-microglobulin serum level is not a marker of disease activity in multiple sclerosis.
|
pubmed:affiliation |
Department of Neurological Sciences, University La Sapienza, Rome. francesca.bagnato@uniroma1.it
|
pubmed:publicationType |
Journal Article
|